Therefore, this study focused on the effect of the widely used antidiabetic peptide Exe-4, a GLP-1 receptor agonist, on DDP chemotherapy in endometrial cancer in the context of hyperglycemia-associated chemoresistance, exploring the underlying mechanism. This evidence concerns the gene GLP1R and endometrial cancer.